Literature DB >> 7332348

Dialysis for psoriasis - preliminary remarks concerning mode of action.

Z Hanicki, T Cichocki, A Klein, O Smoleński, W Sułowicz, J Czabanowska.   

Abstract

In one patient treated by peritoneal dialysis for psoriasis the skin lesions cleared completely. In two persons hemodialysis gave unsatisfactory results. In treated and another three untreated patients cellular immunity was evidently suppressed. This phenomenon is similar to the immunologic changes in persons with uremia. Solutes in middle molecular weight range (SMMWR) suppress cellular immunity. These compounds were therefore investigated in psoriatics. The level of SMMWR was lower before than after each dialysis, although their concentration increased slightly during the dialytic treatment. This suggests that solutes in middle molecular weight are fixed in the epidermis and/or in the walls of the skin capillaries and that dialysis liberates them from these places. Peritoneal dialysis seems to be a more effective method of treating psoriasis than hemodialysis. Solutes in middle molecular weight range might play an important role in the pathomechanisms of this multifactorial disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332348     DOI: 10.1007/bf00406684

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

1.  [Epidermopoietin--a hypothetical psoriatogenic factor].

Authors:  Z Twardowski
Journal:  Przegl Dermatol       Date:  1979 Jan-Feb

2.  Effect of haemodialysis on immune response.

Authors:  E A Gombos; D M Jefferson; J G Bhat
Journal:  Proc Eur Dial Transplant Assoc       Date:  1975

3.  Influence of middle-sized molecule aggregates from dialysate of uremic patients on lymphocyte transformation in vitro.

Authors:  Z Hanicki; T Cichocki; M Sarnecka-Keller; A Klein; Z Komorowska
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. I. Preliminary characteristics.

Authors:  Z Hanicki; M Sarnecka-Keller; A Klein; K Slizowska
Journal:  Clin Chim Acta       Date:  1974-07-15       Impact factor: 3.786

5.  Progress concerning dialysis of psoriatics.

Authors:  P C Anderson
Journal:  Artif Organs       Date:  1979-11       Impact factor: 3.094

6.  Remission of psoriasis during haemodialysis.

Authors:  H L Muston; S Conceicao
Journal:  Br Med J       Date:  1978-02-25

7.  Influence of middle-molecular-weight solutes from dialysate on the migration rate of leukocytes.

Authors:  T Cichocki; Z Hanicki; A Klein; Z Komorowska; M Sarnecka-Keller; W Sułowicz
Journal:  Kidney Int       Date:  1980-02       Impact factor: 10.612

8.  Continuous peritoneal dialysis for treatment of psoriasis. II. Destruction of stratum corneum with peritoneal PMNL serine proteinase.

Authors:  W Gliński; S Jabłońska; M Jarzabek-Chorzelska; Z Zarebska; J Imiela; J Nosarzewski
Journal:  Arch Dermatol Res       Date:  1979-08       Impact factor: 3.017

9.  Some aspects of cellular immunity in untreated and maintenance hemodialysis patients.

Authors:  Z Hanicki; T Cichocki; Z Komorowska; W Sułowicz; O Smoleński
Journal:  Nephron       Date:  1979       Impact factor: 2.847

10.  [Improvement of psoriasis by haemodialysis (author's transl)].

Authors:  I Sprenger-Klasen; H E Franz; O E Rodermund
Journal:  Dtsch Med Wochenschr       Date:  1980-06-27       Impact factor: 0.628

View more
  1 in total

1.  New-onset psoriasis during peritoneal dialysis.

Authors:  Daniël A Geerse; Joëlle Suijkerbuijk; Karen M van Poppelen; Elisabeth J Litjens; Tom Cornelis
Journal:  Perit Dial Int       Date:  2014 Nov-Dec       Impact factor: 1.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.